Real-time Edge Nutromics' lab-on-a-patch delivers continuous real-time molecular data with AI-designed DNA biosensors, enabling clinicians to move beyond delayed snapshots and make faster, better decisions in ICU and critical care, opening opportunities for hospital procurement teams seeking precision dosing and RPM.

Sepsis Opportunity The first product focuses on vancomycin monitoring with active programs in sepsis, cardiology and triage, and recent funding to develop a world-first sepsis management patch, offering hospitals a pathway to improved sepsis protocols, antibiotic stewardship, and reduced cost of care.

Investment Momentum Strong investor and governance signals from Dexcom Ventures and CRC Projects funding, along with a new US-facing chair, indicate credibility and capability to form strategic partnerships, scale manufacturing, and accelerate entry into US and global markets.

Platform Scalability The platform targets multiple molecular markers and can broaden beyond vancomycin, enabling cross-department selling to intensive care units, cardiology, and emergency/triage workflows, aligning with hospital demand for comprehensive continuous monitoring.

US Market Readiness Leadership with US medtech commercialization experience, existing investor networks, and a clear roadmap for sepsis and monitoring patches position Nutromics to pursue US hospital systems, distributors, and pharma partnerships for drug monitoring and real-time diagnostics.